Literature DB >> 22350950

Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.

Wenchao Hu1, Qian Yu, Jie Zhang, Demin Liu.   

Abstract

Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. This study aims to determine whether rosiglitazone and pioglitazone ameliorate renal function through an effect on the expression of chemerin and ChemR23 in streptozotocin-induced diabetic rats. The rats were randomized to control, diabetic, rosiglitazone-, and pioglitazone-treated groups. The expression level of chemerin and ChemR23 in the renal tissues was significantly elevated in the diabetic group compared with the control group. Rosiglitazone inhibited the overexpression of chemerin and ChemR23, while pioglitazone inhibited the overexpression of ChemR23 in the kidney of diabetic rats. In addition, chemerin expression level was positively correlated with transforming growth factor-β1, connective tissue growth factor, tumor necrosis factor-α, and intracellular cell adhesion molecule-1 expression in diabetic rats. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350950     DOI: 10.1007/s10753-012-9440-y

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  31 in total

Review 1.  Insulin resistance and its treatment by thiazolidinediones.

Authors:  H E Lebovitz; M A Banerji
Journal:  Recent Prog Horm Res       Date:  2001

2.  Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.

Authors:  Henrike Sell; Adeline Divoux; Christine Poitou; Arnaud Basdevant; Jean-Luc Bouillot; Pierre Bedossa; Joan Tordjman; Jürgen Eckel; Karine Clément
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

Review 3.  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

Authors:  Pantelis A Sarafidis; Panagiotis C Stafylas; Panagiotis I Georgianos; Athanasios N Saratzis; Anastasios N Lasaridis
Journal:  Am J Kidney Dis       Date:  2010-01-29       Impact factor: 8.860

Review 4.  Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes.

Authors:  G Derosa; P Maffioli
Journal:  Diabetes Res Clin Pract       Date:  2010-09-15       Impact factor: 5.602

5.  Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients.

Authors:  Wenchao Hu; Ping Feng
Journal:  Diabetes Res Clin Pract       Date:  2010-12-07       Impact factor: 5.602

6.  Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice.

Authors:  Fiona Y Chow; David J Nikolic-Paterson; Elyce Ozols; Robert C Atkins; Gregory H Tesch
Journal:  J Am Soc Nephrol       Date:  2005-04-27       Impact factor: 10.121

Review 7.  Current therapies and emerging targets for the treatment of diabetes.

Authors:  A S Wagman; J M Nuss
Journal:  Curr Pharm Des       Date:  2001-04       Impact factor: 3.116

8.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Authors:  Michael Lehrke; Alexander Becker; Martin Greif; Renee Stark; Rüdiger P Laubender; Franz von Ziegler; Corinna Lebherz; Janine Tittus; Maximilian Reiser; Christoph Becker; Burkhard Göke; Alexander W Leber; Klaus G Parhofer; Uli C Broedl
Journal:  Eur J Endocrinol       Date:  2009-06-04       Impact factor: 6.664

10.  Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.

Authors:  Johanna Weigert; Markus Neumeier; Josef Wanninger; Michael Filarsky; Sabrina Bauer; Reiner Wiest; Stefan Farkas; Marcus N Scherer; Andreas Schäffler; Charalampos Aslanidis; Jürgen Schölmerich; Christa Buechler
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-24       Impact factor: 3.478

View more
  13 in total

1.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

2.  Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.

Authors:  Haifeng Huang; Liping Hu; Jiancong Lin; Xiaoxiao Zhu; Weiling Cui; Wenming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Chemerin connects fat to arterial contraction.

Authors:  Stephanie W Watts; Anne M Dorrance; Mark E Penfold; Jillian L Rourke; Christopher J Sinal; Bridget Seitz; Timothy J Sullivan; Trevor T Charvat; Janice M Thompson; Robert Burnett; Gregory D Fink
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-04       Impact factor: 8.311

Review 4.  Bone Marrow Adipose Tissue and Skeletal Health.

Authors:  Shanmugam Muruganandan; Rajgopal Govindarajan; Christopher J Sinal
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

5.  Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes.

Authors:  Alireza Esteghamati; Mehrnaz Ghasemiesfe; Mostafa Mousavizadeh; Sina Noshad; Manouchehr Nakhjavani
Journal:  J Diabetes Investig       Date:  2013-10-22       Impact factor: 4.232

6.  Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease.

Authors:  Hu Yang; Yan Song; Ya-Nan Liang; Rong Li
Journal:  Med Sci Monit       Date:  2018-07-10

7.  Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy.

Authors:  Jin Shang; Luyao Wang; Ya Zhang; Shiyi Zhang; Lina Ning; Jifang Zhao; Genyang Cheng; Dong Liu; Jing Xiao; Zhanzheng Zhao
Journal:  J Cell Mol Med       Date:  2019-02-19       Impact factor: 5.310

8.  Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ.

Authors:  Xiaojing Lin; Yanan Yang; Jing Qu; Xiaohui Wang
Journal:  Nutr Metab (Lond)       Date:  2019-03-05       Impact factor: 4.169

9.  Chemerin as a Driver of Hypertension: A Consideration.

Authors:  David J Ferland; Adam E Mullick; Stephanie W Watts
Journal:  Am J Hypertens       Date:  2020-11-03       Impact factor: 2.689

10.  Increased Circulating Chemerin in Relation to Chronic Microvascular Complications in Patients with Type 2 Diabetes.

Authors:  Ping Gu; Wei Wang; Yue Yao; Yixin Xu; Liping Wang; Pu Zang; Jian Ma; Cuihua Yang; Junya Liang; Bin Lu; Jiaqing Shao
Journal:  Int J Endocrinol       Date:  2019-07-16       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.